Human LIF Antibody
R&D Systems, part of Bio-Techne | Catalog # AB-250-NA
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, Rabbit
Applications
Validated:
Western Blot, Neutralization
Cited:
Neutralization, ELISA Capture
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
E. coli-derived recombinant human LIF
Ser23-Phe202
Accession # P15018
Ser23-Phe202
Accession # P15018
Specificity
Detects human LIF in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 25% cross-reactivity with recombinant mouse LIF is observed. Neutralizes the biological activity of recombinant human LIF and will also neutralize the biological activity of recombinant mouse LIF at a 50-fold higher IgG concentration.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human LIF Antibody
Cell Proliferation Induced by LIF and Neutralization by Human LIF Antibody.
Recombinant Human LIF (Catalog # 7734-LF) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line) as measured by Resazurin (Catalog # AR002). Proliferation elicited by 0.5 ng/mL Recom-binant Human LIF is neutralized (green line) by increasing concentrations of Goat Anti-Human LIF Polyclonal Antibody (Catalog # AB-250-NA). The ND50 is typically 0.1-0.4 µg/mL.Detection of LIF by Western Blot
LIF neutralizing antibody inhibits the migration and invasion capability and the Stat3 phosphorylation induced by CAA-CM on breast cancer cells. (A and B) MDA-MD-231 cells cultured in Adi-CM or CAA-CM or control DMEM were treated with LIF neutralizing antibody/IgG. The cell migration (A) and invasion (B) situation were monitored under a phase contrast microscope. The corresponding quantization chart is shown on the right. (C) MDA-MB-231 cells were treated with different culture media for 15 min, and Stat3 phosphorylation was analyzed by western blot. (D) MDA-MD-231 cells cultured in DMEM or Adi-CM or CAA-CM were treated with LIF neutralizing antibody or IgG for 15 min, and Stat3 phosphorylation was analyzed by western blot. Typical microscopic fields and blots are shown and quantitative data are presented as mean ± SD from at least three independent experiments. #p < 0.05, ##p < 0.01, ###p < 0.001, CAA-CM VS. Mock; *p < 0.05, **p < 0.01, ***p < 0.001, CAA-CM + alpha-LIF VS. CAA-CM. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35280694), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of LIF by Immunohistochemistry
Knockdown of endogenous Stat3 with siRNA inhibits the migration and invasion of breast cancer cells induced by CAA-CM and rhLIF. (A-D) MDA-MB-231 cells transfected with siRNA were treated with rhLIF (A and B) or CAA-CM (C and D) to observe cell migration and invasion. (E) The expression of LIF and Stat3 phosphorylation in normal breast tissue and breast cancer tissue was analyzed by IHC, scale bar: 100 μm. (F) The correlation between the relative expression of LIF and Stat3 phosphorylation in human breast cancer sections. Typical microscopic fields and blots are shown and quantitative data are presented as mean ± SD from at least three independent experiments. #p < 0.05, ##p < 0.01, ###p < 0.001, NS + rhLIF or CAA-CM VS. NS; *p < 0.05, **p < 0.01, ***p < 0.001, siRNA+rhLIF or CAA-CM VS. NS + rhLIF or CAA-CM. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35280694), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human LIF Antibody
Application
Recommended Usage
Western Blot
0.1 µg/mL
Sample: Recombinant Human LIF
Sample: Recombinant Human LIF
Neutralization
Measured by its ability to neutralize LIF-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND50) is typically 0.1-0.4 µg/mL in the presence of 0.5 ng/mL Recombinant Human LIF.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Reconstitution
Reconstitute at 1 mg/mL in sterile PBS.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: LIF
Long Name
Leukemia Inhibitory Factor
Alternate Names
D Factor, Emfilermin, HILDA, MLPLI
Gene Symbol
LIF
UniProt
Additional LIF Products
Product Documents for Human LIF Antibody
Product Specific Notices for Human LIF Antibody
For research use only
Loading...
Loading...
Loading...
Loading...